A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Trial Profile

A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2015

At a glance

  • Drugs Bortezomib (Primary) ; Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone; Filgrastim; Granulocyte colony-stimulating factors; Lenalidomide; Pomalidomide; Thalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jul 2013 Planned end date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 25 Jan 2013 Investigational drug identified as 'carfilzomib' as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top